Fluicell AB (FRA:5J90) OCF Margin %: 4.06% (As of Mar. 2026)


FRA:5J90 Fluicell AB FRA:5J90
57 GF Score
Price €2.55
GF Value €2.92
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Fluicell AB OCF Margin %?

Fluicell AB FRA:5J90 -11.15% 57 OCF Margin % is 4.06% as of Mar. 2026. GuruFocus rates FRA:5J90 with a GF Score™ of 57/100 and a GF Value™ of €2.92 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Fluicell AB ranks better than 63.4% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Fluicell AB's Cash Flow from Operations for the three months ended in Mar. 2026 was €0.02 Mil. Fluicell AB's Revenue for the three months ended in Mar. 2026 was €0.57 Mil. Therefore, Fluicell AB's OCF Margin % for the quarter that ended in Mar. 2026 was 4.06%.

As of today, Fluicell AB's current OCF Yield % is -2.00%.

The historical rank and industry rank for Fluicell AB's OCF Margin % or its related term are showing as below:

FRA:5J90' s OCF Margin % Range Over the Past 10 Years
Min: -1016.48   Med: -701.21   Max: -82.37
Current: -7.59


During the past 11 years, the highest OCF Margin % of Fluicell AB was -82.37%. The lowest was -1016.48%. And the median was -701.21%.

FRA:5J90's OCF Margin % is ranked better than
63.4% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs FRA:5J90: -7.59


Fluicell AB OCF Margin % Related Terms


Fluicell AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for Fluicell AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fluicell AB OCF Margin % Chart

Fluicell AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -717.39 -646.62 -816.78 -840.74 -82.25

Fluicell AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,647.62 -407.81 -100.00 75.85 4.06

FRA:5J90 vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Fluicell AB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fluicell AB OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fluicell AB's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Fluicell AB's OCF Margin % falls into.


FRA:5J90
57GF Score
Fluicell AB FRA:5J90
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fluicell AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Fluicell AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.454/0.552
=-82.25 %

Fluicell AB's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0.023/0.566
=4.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 4.06% mean?
Fluicell AB (FRA:5J90) has a OCF Margin % of 4.06% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fluicell AB and its competitors. According to the industry distribution chart, Fluicell AB ranks #351 out of 959 companies in the Biotechnology industry, placing it in the top 36.6%.
Is Fluicell AB's OCF Margin % too high?
Fluicell AB's current OCF Margin % is 4.06%. Based on the distribution chart, Fluicell AB ranks #351 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fluicell AB has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #351 out of 959 companies for OCF Margin %. This puts Fluicell AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fluicell AB and its competitors. Fluicell AB's current OCF Margin % is 4.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (FRA:5J90) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.92, compared to a current price of €2.55 — trading 12.7% below its estimated fair value. The current OCF Margin % is 4.06%. Fluicell AB's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Fluicell AB (FRA:5J90), the current OCF Margin % is 4.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fluicell AB (FRA:5J90) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued. The current stock price of €2.55 is trading 12.7% below its estimated GF Value™ of €2.92. GuruFocus considers Fluicell AB to be Modestly Undervalued.

Key valuation signals for FRA:5J90:

  • OCF Margin %: 4.06%
  • GF Value™: €2.92 vs. price of €2.55 (12.7% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:5J90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fluicell AB Business Description

Other Exchanges FLUI:Sweden
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
57GF Score

Get the complete analysis for FRA:5J90

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€2.92
GF Value